The Journal of Innovative Therapeutics and Drug Care (JITDC) is committed to publishing timely and impactful research that shapes the future of pharmaceutical science and clinical drug management. Our archives serve as a valuable resource for researchers, practitioners, educators, and students across the globe.
Featured Articles in the Latest Issue
- Volume 1 (Issue 2) JULY– DECEMBER 2025
Research Articles
Evaluating Hidden Safety Hazards of Inactive Ingredients in Herbal Pediatric Cough Syrups: Repercussions for Pharmacist-Led Interventions
Vol.1(2); Pages:1-8. Published on July-2025
Abstract
Doctors usually rely on pediatric over-the-counter phytomucolytic syrups to ease cough symptoms in children. Doctors and scientists often pay attention to how plant-based ingredients work, but tend to forget about the safety and impact of excipients, which are classified as “inactive.” Still, it is widely known that many of these supplements may lead to harmful side effects or clash with what you are already taking. The research compares and reviews excipient contents of the most famous pediatric phytomucolytic syrups sold in both Ukraine and Germany. It was aimed at finding out about the hazards linked to these excipients and coming up with a way for pharmacists to offer better care for patients. The investigation revealed that all of the products except one contained ingredients that scientists deem hazardous, for example artificial sweeteners, dyes, and parabens. Results of the analysis call for creating a decision-making model where pharmacists are guided to handle risks from excipients in pediatric syrups during selection and dispensing. Paying special attention to excipients’ safety allows pharmacists to improve the health of kids and the success of cough treatments.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Sublingual ketamine: a pilot study on clinical evaluation of rapid treatment of suicidal ideation in treatment-resistant depression
Vol.1(2); Pages:9-16. Published on August-2025
Abstract
Sublingual ketamine is becoming an alternative possible route in the treatment of acute suicidal thoughts, especially those towards patients that are resistant to the regular antidepressants. This was a pilot open label trial to test safety, tolerability, and the quick antidepressant effect of sublingual ketamine administration in patients with treatment resistant depression (TRD), with active suicidal thoughts. Through the evaluation of 10 adult patients with mild-to-severe depression over a two-week period and twice per week, 100 mg of sublingual ketamine was used and the subjects were followed up on day 1, 4, 7 and 14 using the Columbia-Suicide Severity Rating Scale (C-SSRS), MADRS, and CGI scales. Significant improvements were also seen in the suicidal ideation in 70 percent of the patients within 4 hours after taking the drug and persisted through day 14. Side effects were limited (dizziness, nausea) and there were no psychotic symptoms. There was great patient tolerability, and clinician acceptability of the intervention. These initial findings lead to the possibility of sublingual ketamine as a quick and available avenue of therapeutics of psychiatric emergencies and should be followed up with other randomized controlled studies to justify efficacy.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Combination of Niclosamide and Metformin for Glycemic Management of Type 2 Diabetes: A Pilot Study
Vol.1(2); Pages:17-25. Published on September-2025
Abstract
The aim of this randomized open-label pilot study is to study the effectiveness of the combination of niclosamide, a repurposed anthelmintic, and metformin to treat glycemic control in adults having poorly controlled Type 2 Diabetes Mellitus (T2DM). Forty patients were recruited arbitrarily into 2 arms; one arm was used with 1000 mg BID metformin and the other arm with 1000 mg BID metformin coupled with 500 mg BID niclosamide taken 12 weeks each. The major outcomes such as HbA1c, fasting plasma glucose (FPG), insulin resistance (HOMA-IR) were improved significantly in the combination therapy group than in the metformin group. The combination group showed an average decrease in HbA1c of -1.6% compared to metformin group of -0.9 ( p < 0.05 ). There were cases of mild gastrointestinal discomfort in 20 percent of participants. Such observations justify the prospect of niclosamide repurposing in the management of T2DM, especially in low-resource contexts.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Liposomal Targeted Delivery of Dexamethasone in Inflammatory Bowel Disease Efficacy and Safety Evaluation
Vol.1(2); Pages:26-35. Published on October-2025
Abstract
In this work, the potential of dexamethasone-loaded liposomes as an alternative to the current systemic application of the drug in the targeted treatment of inflammatory bowel disease (IBD) is being investigated, with the purpose of minimizing its systemic toxicity and maximizing its anti-inflammatory effect. Liposomes were generated by thinfilm hydration-based method, and optical characterization of liposomes included lipos +, zeta potential, encapsulation degree and release profile of liposomes +. It has been shown in vitro on Caco2 and RAW 264.7 cell lines that there is increased cellular uptake and inhibition of TNF-a and IL-6 production. Pharmacological analysis in an animal model of TNBS-induced colitis followed by histopathological examination on the Wistar rat indicated that liposomal formulation of dexamethasone decreased the disease activity index, weight/length ratio of the colonic segments, and pathological damage significantly (p < 0.01). Also, liposomal dexamethasone reduced the adverse effects of corticosteroids, including adrenal suppression and weight loss. These results justify liposomal dexamethasone as a secure, proficient, and localized therapy against IBD.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Long-Acting Risperidone vs Standard Care in First-Episode Schizophrenia: A 12-Month Study
Vol.1(2); Pages:36-42. Published on November-2025
Abstract
The present multinational, prospective observational study compared clinical outcomes in terms of the efficacy and safety of long-acting injectable (LAI) risperidone administered in first-episode schizophrenia (FES) patients within 12 months. Among the patients were 124 Brazilians and Netherlands whose enrollment and follow-up were done. The main outcomes were the rates of relapse, drug compliance, the number of admissions, and side effects. Relapse rates among patients treated with LAI risperidone were significantly reduced (15.3%), in comparison with historical oral antipsychotic cohorts (32.1%), and the adherence scores improved, and a 42% of the psyche patients reduced in the number of hospitalizations. Extrapyramidal effects were also mild and only 18 percent of the patients showed such effects without any significant safety issues. These findings demonstrate the relevance of early-stage intervention in LAI risperidone in first-episode schizophrenia, which provides a long-term stabilizing course and enhancement of functional outcomes in real-life practice.
View Full PDF
Please LOGIN to View Full PDF or Read more.
Accessing the Articles
You can access the full text of these articles by clicking on the titles or visiting our journal’s online archives.
Stay Updated
To stay informed about the latest research and updates in the journal, consider subscribing to our newsletter or following us on social media.
